title: Hepatitis C virus distribution and clearance following interferon-monotherapy among thalassaemia major and intermedia patients.
authors.forename: Paolo
authors.initials: P
authors.lastname: Ricchi
authors.forename: Alfonso G
authors.initials: AG
authors.lastname: Lanza
authors.forename: Massimiliano
authors.initials: M
authors.lastname: Ammirabile
authors.forename: Silvia
authors.initials: S
authors.lastname: Costantini
authors.forename: Patrizia
authors.initials: P
authors.lastname: Cinque
authors.forename: Anna
authors.initials: A
authors.lastname: Spasiano
authors.forename: Tiziana
authors.initials: T
authors.lastname: Di Matola
authors.forename: Giovan G
authors.initials: GG
authors.lastname: Di Costanzo
authors.forename: Leonilde
authors.initials: L
authors.lastname: Pagano
authors.forename: Luciano
authors.initials: L
authors.lastname: Prossomariti
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D005260:Female; D016174:Hepacivirus / Q000302:isolation & purification*; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000821:virology*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000627:therapeutic use; D013789:Thalassemia / Q000821:virology*; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; C100416:peginterferon alfa-2a